牛牛AI助理已提取核心訊息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market under the trading symbol HSCS, successfully held a reconvened Annual Meeting on February 15, 2024. The purpose of the meeting was to vote on Proposal 7, which aimed to amend the company's Certificate of Formation to decrease the number of shares required to establish a quorum for shareholder meetings. This proposal was previously presented at the Annual Meeting on January 17, 2024, but did not receive sufficient votes to pass. Following additional solicitation of votes, shareholders approved the amendment with 27,172,440 votes for, 1,298,890 against, 362,117 abstentions, and 1,015,919 broker non-votes. The details of the proposal were outlined in the definitive proxy statement filed with the SEC on December 8, 2023. Heart Test Laboratories is identified as an emerging growth company and has its principal executive offices in Southlake, Texas.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market under the trading symbol HSCS, successfully held a reconvened Annual Meeting on February 15, 2024. The purpose of the meeting was to vote on Proposal 7, which aimed to amend the company's Certificate of Formation to decrease the number of shares required to establish a quorum for shareholder meetings. This proposal was previously presented at the Annual Meeting on January 17, 2024, but did not receive sufficient votes to pass. Following additional solicitation of votes, shareholders approved the amendment with 27,172,440 votes for, 1,298,890 against, 362,117 abstentions, and 1,015,919 broker non-votes. The details of the proposal were outlined in the definitive proxy statement filed with the SEC on December 8, 2023. Heart Test Laboratories is identified as an emerging growth company and has its principal executive offices in Southlake, Texas.
Heart Test Laboratories, Inc. 是一家在納斯達克股票市場上市的公司，交易代碼爲HSCS，該公司於2024年2月15日成功舉行了續會的年會。會議的目的是對第7號提案進行表決，該提案旨在修改公司的成立證書，以減少確定股東大會法定人數所需的股票數量。該提案此前曾在2024年1月17日的年會上提出，但沒有獲得足夠的選票通過。在進一步徵集投票後，股東們以27,172,440票贊成、1,298,890票反對、362,117票棄權和1,015,919張經紀人無票批准了該修正案。該提案的細節已在2023年12月8日向美國證券交易委員會提交的最終委託書中概述。心臟測試實驗室被確定爲一家新興的成長型公司，其主要執行辦公室位於德克薩斯州的紹斯萊克。
Heart Test Laboratories, Inc. 是一家在納斯達克股票市場上市的公司，交易代碼爲HSCS，該公司於2024年2月15日成功舉行了續會的年會。會議的目的是對第7號提案進行表決，該提案旨在修改公司的成立證書，以減少確定股東大會法定人數所需的股票數量。該提案此前曾在2024年1月17日的年會上提出，但沒有獲得足夠的選票通過。在進一步徵集投票後，股東們以27,172,440票贊成、1,298,890票反對、362,117票棄權和1,015,919張經紀人無票批准了該修正案。該提案的細節已在2023年12月8日向美國證券交易委員會提交的最終委託書中概述。心臟測試實驗室被確定爲一家新興的成長型公司，其主要執行辦公室位於德克薩斯州的紹斯萊克。
有用
沒用